Vaccination clinic begins Tuesday at MD Anderson
Following receipt of the Pfizer COVID-19 vaccine on Monday morning, MD Anderson’s Pharmacy, Infection Control, Employee Health and clinical and facilities experts re-reviewed protocols and procedures, and an initial vaccination clinic simulation was completed. Based on those successful efforts along with a manager briefing and employee town hall, positive feedback from managers about employee engagement and swift uptake of appointment...
MD Anderson researcher elected to ASCO Board of Directors
Mariana Chavez Mac Gregor, M.D., M.Sc., associate professor in Health Services Research with a joint appointment in Breast Medical Oncology...
COVID-19 vaccine delivery and distribution statement from MD Anderson
The University of Texas MD Anderson Cancer Center is prepared to accept, store and distribute the Pfizer COVID-19 vaccine following the Food...
Combination of chemotherapy and blinatumomab improves survival for patients with B-cell acute lymphoblastic leukemia
ABSTRACT 464
A study led by The University of Texas MD Anderson Cancer Center showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab resulted in increased survival and achieved a high rate of measurable residual disease (MRD) negativity for patients who were newly diagnosed with a high-risk form of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-negative...
CAR T cell therapy effective as first-line treatment for high-risk large B-cell lymphoma
ABSTRACT 405
A study led by researchers at The University of Texas MD Anderson Cancer Center found that axi-cel, an autologous anti-CD19...
Novel antibody-drug conjugate shows promising early results in rare blood cancer
ABSTRACT 167
A phase I/II study led by researchers from The University of Texas MD Anderson Cancer Center found IMGN632, a novel CD123...
Five MD Anderson researchers elected AAAS Fellows
In recognition of their achievements in advancing cancer research, five faculty members from The University of Texas MD Anderson ...
New targeted therapy blocks metabolism in brain cancer cells with genetic vulnerability
Researchers at The University of Texas MD Anderson Cancer Center have developed a novel targeted therapy, called POMHEX, which blocks critical...
MD Anderson joins thousands of top U.S. hospitals encouraging everyone to #MaskUp
The University of Texas MD Anderson Cancer Center and more than 100 of the nation’s top health care systems, representing thousands of hospitals...
A Conversation With a Living Legend honoring Admiral William H. McRaven raises $1 million
The North Texas A Conversation With a Living Legend® raised $1 million this week in a virtual version of the signature fundraising event benefiting...
MD Anderson and Obsidian Therapeutics announce strategic collaboration to accelerate advancement of novel engineered tumor infiltrating lymphocyte therapy (cytoTIL™) for solid tumors
The University of Texas MD Anderson Cancer Center and Obsidian Therapeutics, Inc. today announced a multi-year strategic collaboration designed...
Sherry Adkins receives Brown Foundation Award for Excellence in Oncology Nursing
Sherry Adkins is the recipient of the 2020 Brown Foundation Award for Excellence in Oncology Nursing at The University of Texas MD Anderson...
MD Anderson announces fifth annual class of Andrew Sabin Family Fellows
The University of Texas MD Anderson Cancer Center has named 10 early-career faculty members to the 2020 class of Andrew Sabin Family Fellows...
MD Anderson researchers present immunotherapy advances at Society for Immunotherapy of Cancer Annual Meeting
ABSTRACTS 277, 368, 420
Promising clinical results with combination treatments for patients with melanoma and lung cancer highlight...
Large-scale cancer proteomics study profiles protein changes in response to drug treatments
Through large-scale profiling of protein changes in response to drug treatments in cancer cell lines, researchers at The University of Texas...
MD Anderson and UT Austin collaboration to end cancer welcomed enthusiastically by state and federal stakeholders
A new collaboration combining cancer research with advanced computing and computational modeling techniques received strong engagement and...
Stereotactic radiosurgery recommended for patients with more than three brain metastases
Researchers from The University of Texas MD Anderson Cancer Center have conducted the first randomized clinical trial comparing stereotactic...
MD Anderson's fifth annual Boot Walk to End Cancer® goes virtual Nov. 7
HOUSTON ― The University of Texas MD Anderson Cancer Center will host the fifth annual Boot Walk to End Cancer® virtually on Saturday, Nov...
Focus Fund and MD Anderson launch investment fund to support promising investigational cancer therapies in early-stage clinical trials
The Focus Fund GP, LLC, in partnership with The University of Texas MD Anderson Cancer Center, has launched Cancer Focus Fund, LP, an oncology-focused...
MD Anderson, UT Austin Announce First Collaborative Projects in United Fight to End Cancer
Cancer remains one of the leading causes of death worldwide. While advances in cancer diagnoses and treatments are promising, more is needed...
MD Anderson and Allogene Therapeutics announce strategic collaboration to accelerate advancement of allogeneic CAR T therapy (AlloCAR T)
The University of Texas MD Anderson Cancer Center and Allogene Therapeutics, Inc. today announced a strategic five-year collaboration agreement...
MD Anderson earns fifth Magnet designation for nursing excellence
The University of Texas MD Anderson Cancer Center today announced achievement of its fifth consecutive Magnet designation, the highest distinction...
Dual checkpoint blockade promising as pre-surgical approach for certain patients with localized bladder cancer
Neoadjuvant, or pre-surgical, combination treatment with the immune checkpoint inhibitors tremelimumab (anti-CTLA-4) and durvalumab (anti-PD...
Study identifies characteristics of infused CAR T cells associated with efficacy and toxicity in patients with large B-cell lymphoma
Researchers at The University of Texas MD Anderson Cancer Center have identified molecular and cellular characteristics of anti-CD19...
Study finds cancer mutations accumulate in distinct regions based on structure of genome and mutational causes
A new study from researchers at The University of Texas MD Anderson Cancer Center has discovered that mutations found in cancers do not accumulate...
Next-gen bioinformatics tool enables big data analysis without programming expertise
A new data analysis tool developed by researchers at The University of Texas MD Anderson Cancer Center incorporates a user-friendly,...
MD Anderson and Taiho Pharmaceutical announce collaboration to accelerate development of novel therapies for brain metastasis and other unmet medical needs
The University of Texas MD Anderson Cancer Center and Taiho Pharmaceutical Co., Ltd., today announced a three-year strategic collaboration...
Monica Johnson receives Julie and Ben Rogers Award for Excellence
The University of Texas MD Anderson Cancer Center has awarded Monica Johnson, M.H.A., C.P.X.P., the Julie and Ben Rogers Award for Excellence...
KRAS inhibitor sotorasib appears safe, achieves durable clinical benefit in early trial
ABSTRACT: 1257O
In a Phase I clinical trial for patients with advanced solid cancers marked by KRAS G12C mutations, the KRASG12C inhibitor...
New study from MD Anderson and BridgeBio’s Navire Pharma shows SHP2 inhibition overcomes multiple therapeutic-resistance mechanisms in lung cancer
New preclinical research from The University of Texas MD Anderson Cancer Center and BridgeBio Pharma, Inc. affiliate Navire Pharma, Inc...
Combination immunotherapy benefits subset of patients with advanced prostate cancer
Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center suggest that a combination of ipilimumab...
MD Anderson and Astex Pharmaceuticals announce strategic collaboration to accelerate clinical evaluation of therapies for patients with leukemia
The University of Texas MD Anderson Cancer Center and Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co....
MD Anderson and Xencor enter strategic collaboration to advance investigational XmAb® drug candidates
The University of Texas MD Anderson Cancer Center and Xencor, Inc. today announced a strategic collaboration to study investigational...
MD Anderson welcomes 15 volunteer board members, honors two new Life Members
The University of Texas MD Anderson Cancer Center Board of Visitors (BOV) has named 15 new members and bestowed its highest honor of Life...
Lung cancer trial of RET inhibitor selpercatinib achieves durable responses in majority of patients with RET gene fusions
For patients with non-small cell lung cancers (NSCLC) marked by RET gene fusions, the targeted therapy selpercatinib was well tolerated and...
$24 million in CPRIT funding awarded to MD Anderson and related research
The University of Texas MD Anderson Cancer Center today was awarded nearly $9 million from the Cancer Prevention and Research Institute...
Targeted therapy combination effective for patients with advanced cholangiocarcinoma and BRAF mutations
In a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, the combination of dabrafenib, a BRAF inhibitor...
Study shows frequently used serology test may not detect antibodies that could confirm protection against reinfection of COVID-19
Two different types of detectable antibody responses in SARS-CoV-2 (COVID-19) tell very different stories and may indicate ways to enhance...
Combination therapy significantly improves survival outcomes for patients with acute myeloid leukemia
A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over azacitidine alone in certain patients...
Cancer care and screenings must remain a priority during COVID-19
The University of Texas MD Anderson Cancer Center is committed to safely providing patient care and cancer screenings throughout the novel...
Implementation of social distancing policies correlates with significant reduction in SARS-CoV-2 transmission
According to researchers from The University of Texas MD Anderson Cancer Center, the implementation of social distancing policies corresponded...
MD Anderson honored to rank as nation’s best hospital for cancer care
The University of Texas MD Anderson Cancer Center is honored to rank No. 1 in cancer care in the U.S. News & World Report’s 2020...
MD Anderson and Sanofi announce strategic collaboration to accelerate oncology research and development
The University of Texas MD Anderson Cancer Center and Sanofi today announced a five-year strategic collaboration to accelerate the development...
MD Anderson and UT Austin Create Unique Data-Driven Collaboration to Eliminate Cancer Using Novel Mathematical and Computational Approaches
The University of Texas MD Anderson Cancer Center and two institutions at The University of Texas at Austin – the Oden Institute for Computational...
Public Notice of Scheduled Site Visit to MD Anderson by ANCC Magnet Recognition Program Appraisers
Public Notice
MAGNET RECOGNITION PROGRAM® — SITE VISIT
· The University of Texas...
Study shows sedentary behavior independently predicts cancer mortality
In the first study to look at objective measures of sedentary behavior and cancer mortality, researchers from The University of Texas MD Anderson...
Combination biomarker predicts response to immune checkpoint therapy in patients with advanced bladder cancer
In patients with metastatic bladder cancer, a novel combination of biomarkers from baseline tumor tissues was predictive of improved clinical...
MD Anderson and Philips collaborate to facilitate personalized oncology treatments and clinical trial matching based on genomic markers
The University of Texas MD Anderson Cancer Center and Royal Philips today announced a collaboration to provide oncologists with evidence-based...
MD Anderson and Rakuten Medical announce strategic alliance to advance Illuminox platform for cancer treatments
The University of Texas MD Anderson Cancer Center and Rakuten Medical, Inc. today announced a strategic alliance collaboration agreement to...
Statement from Peter WT Pisters, M.D., regarding the tragic death of George Floyd
At MD Anderson, we are filled with anguish and deep sorrow over the senseless acts of racism and violence in our country and the tragic death...
Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4 shows early activity in patients with advanced solid tumors
ABSTRACT: #102
The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4...
Targeted therapy pralsetinib achieves high response rates in advanced cancers with RET gene fusions
ABSTRACT: #109
The targeted therapy pralsetinib appears to have high response rates and durable activity in patients with a broad variety...
Targeted therapy tepotinib for non-small cell lung cancer with MET exon 14 skipping mutation shows durable response
Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping mutation had a 46.5% objective response rate...
Novel targeted drug induced positive response for patients with von Hippel-Lindau disease–associated kidney cancer
ABSTRACT: #5003
In an international trial led by researchers at The University of Texas MD Anderson Cancer Center, treatment with...
Combination therapy well-tolerated and highly effective for patients with IDH1-mutated acute myeloid leukemia (AML)
ABSTRACT: #7500
A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective...
MD Anderson and Innovent Biologics announce a strategic collaboration to develop anti-PD-1 therapy TYVYT® (sintilimab injection) in rare cancers
The University of Texas MD Anderson Cancer Center and Innovent Biologics, Inc. today announced a strategic collaboration agreement to co-develop...
Patients with advanced BRCA-mutated breast cancer found no overall survival benefit with talazoparib
ABSTRACT: CTO71
New data from the Phase III EMBRACA trial led by researchers at The University of Texas MD Anderson Cancer Center...
MD Anderson, Ipsen advance new therapy with potential benefit for underserved lung and ovarian cancer patients
ABSTRACT: DDT01-03
In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1), researchers...
MD Anderson genetics expert Guillermina Lozano elected to American Academy of Arts and Sciences
Guillermina Lozano, Ph.D., chair of Genetics at The University of Texas MD Anderson Cancer Center, has been elected as...
MD Anderson implements proactive measures due to 2019 novel coronavirus disease (COVID-19)
The University of Texas MD Anderson Cancer Center is committed to keeping our patients, our workforce members and our community safe throughout...
Majority of patients responded in CAR T-cell trial for mantle cell lymphoma
A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell lymphoma...
Immunotherapy effective in metastatic prostate cancers with specific markers of immune activation
Although metastatic castration-resistant prostate cancer (mCRPC) typically has limited response to immunotherapy, a subset of patients with...
New therapeutic strategies proposed for some lung and kidney cancers
New findings from researchers at The University of Texas MD Anderson Cancer Center about how some cancer cells become “addicted” to glucose...
Combination creates powerful central memory T cells for cellular therapy
Treating T cells harvested from a patient with a combination of an epigenetic drug and a cytokine while expanding the cells in the lab re-programs...
Study sheds light on fatty acid’s role in “chemobrain” and multiple sclerosis
Medical experts have always known myelin, the protective coating of nerve cells, to be metabolically inert. A study led by The University...
Pembrolizumab shows promise for some advanced, hard-to-treat rare cancers
A study conducted by researchers at The University of Texas MD Anderson Cancer Center demonstrated acceptable toxicity and anti-tumor activity...
MD Anderson returning to normal operations on Monday, March 2
The University of Texas MD Anderson Cancer Center is preparing to return to normal operations on Monday morning, March 2, after operating...
Combined therapy may improve clinical responses for endometrial, colorectal and gastric tumors
A study at The University of Texas MD Anderson Cancer Center discovered a novel therapeutic vulnerability for patients who have tumors caused...
Osteosarcoma profiling reveals why immunotherapy remains ineffective
Comprehensive profiling of tumor samples taken from patients with osteosarcoma shows that multiple factors contribute to the traditionally...
MD Anderson announces strategic collaboration with Denali Therapeutics to research and develop targeted therapies for neurodegenerative diseases
The University of Texas MD Anderson Cancer Center today announced a strategic research collaboration with Denali Therapeutics Inc. to develop...
MD Anderson receives more than $20 million in CPRIT funding
The University of Texas MD Anderson Cancer Center today was awarded more than $20 million from the Cancer Prevention and Research Institute...
Houston Dash join Dynamo, MD Anderson in Making Cancer History
The University of Texas MD Anderson Cancer Center today announced the Houston Dash will join the institution's efforts toward one goal...
Absent p53, oral cancers recruit and reprogram nerves to fuel tumor growth
Loss of an important tumor-suppressing gene allows head and neck cancer to spin off signals to nearby nerves, changing their function and...
CD19 CAR NK-cell therapy achieves 73% response rate in patients with leukemia and lymphoma
According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric...
Study provides new understanding of mitochondria genome with potential for new avenues of treatment for multiple cancers
A study led by The University of Texas MD Anderson Cancer Center furthered understanding about mitochondria, the cell components known as...
MD Anderson supports World Cancer Day through dedication to eliminate cancer
The University of Texas MD Anderson Cancer Center honors World Cancer Day, Feb. 4, as the campaign celebrates 20 years of bringing awareness...
Study demonstrates liquid biopsy as effective predictor of stage III melanoma relapse and treatment
A study at The University of Texas MD Anderson Cancer Center showed that circulating tumor cells (CTCs), a form of liquid biopsy, was independently...
Lung cancer screening decision aid delivered through tobacco quitlines improves informed decision-making
In the first comparative clinical trial of lung cancer screening decision aid versus standard educational information, researchers from The...
MD Anderson’s deemed status restored; re-accreditation completed
The University of Texas MD Anderson Cancer Center has announced that the Texas Health and Human Services Commission, on behalf of the Centers...
Craig Owen Named Chief Information Officer
The University of Texas MD Anderson Cancer Center today named Craig Owen as its chief information officer. Owen has served the institution...
B-cell enrichment predictive of immunotherapy response in melanoma, sarcoma and kidney cancer
The likelihood of a patient responding to immune checkpoint blockade may depend on B cells in the tumor, located within specialized immune-cell...
Study shows protein inhibitor as potential treatment approach for common mutations found in non-Hodgkin lymphomas
A study at The University of Texas MD Anderson Cancer Center demonstrated a potential new approach to treating two of the most common subtypes...